Attached files
| file | filename |
|---|---|
| EX-32.2 - EXHIBIT 32.2 - Travere Therapeutics, Inc. | exhibit322-1231201610k.htm |
| EX-32.1 - EXHIBIT 32.1 - Travere Therapeutics, Inc. | exhibit321-1231201610k.htm |
| EX-31.2 - EXHIBIT 31.2 - Travere Therapeutics, Inc. | exhibit312-1231201610k.htm |
| EX-31.1 - EXHIBIT 31.1 - Travere Therapeutics, Inc. | exhibit311-1231201610k.htm |
| EX-21.1 - EXHIBIT 21.1 - Travere Therapeutics, Inc. | exhibit211-1231201610k.htm |
| EX-10.34 - EXHIBIT 10.34 - Travere Therapeutics, Inc. | exhibit1034-1231201610k.htm |
| 10-K - 10-K - Travere Therapeutics, Inc. | rtrx-20161231x10k.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
Retrophin, Inc.
San Diego, California
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-202861) and Form S-8 (No. 333-213599) of Retrophin, Inc. of our reports dated March 1, 2017, relating to the consolidated financial statements and the effectiveness of Retrophin, Inc.’s internal control over financial reporting, which appear in this Form 10-K.
/s/ BDO USA, LLP
New York, New York
March 1, 2017